| 000 | 01842 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250516090201.0 | ||
| 264 | 0 | _c20130131 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a1097-0142 | ||
| 024 | 7 |
_a10.1002/cncr.27506 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDefina, Marzia | |
| 245 | 0 | 0 |
_aEvaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. _h[electronic resource] |
| 260 |
_bCancer _cNov 2012 |
||
| 300 |
_a5265-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntigens, CD34 _xmetabolism |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBone Marrow Cells _xpathology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Chronic-Phase _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplastic Stem Cells _xpathology |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrimidines _xtherapeutic use |
| 700 | 1 | _aIppoliti, Micaela | |
| 700 | 1 | _aGozzetti, Alessandro | |
| 700 | 1 | _aAbruzzese, Elisabetta | |
| 700 | 1 | _aCastagnetti, Fausto | |
| 700 | 1 | _aCrupi, Rosaria | |
| 700 | 1 | _aTiribelli, Mario | |
| 700 | 1 | _aBreccia, Massimo | |
| 700 | 1 | _aSalvucci, Marzia | |
| 700 | 1 | _aAprile, Lara | |
| 700 | 1 | _aBaratè, Claudia | |
| 700 | 1 | _aGozzini, Antonella | |
| 700 | 1 | _aRosti, Gianantonio | |
| 700 | 1 | _aLauria, Francesco | |
| 700 | 1 | _aBocchia, Monica | |
| 773 | 0 |
_tCancer _gvol. 118 _gno. 21 _gp. 5265-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.27506 _zAvailable from publisher's website |
| 999 |
_c21716538 _d21716538 |
||